In their second quarter earning statement, Genzyme provided an update on the situation at the Allston manufacturing plant, and the US LumizymeA form of enzyme replacement therapy used to treat Pompe disease by providing a lab-made version of the GAA enzyme. application.
To read full statement, please click here.